I would say near or even under $6 as this is very easy to see what is going on. I think in less than 2 weeks the price will be under 3 and it might get back little but not much as there is huge dark shadow on the results and future of NDA application where FDA is known in cases like this very conservative and CRL letter is most likely to see .
wow, institutions expect stock to fall . I think they bet on secondary offering what of course would price the stock about at the best 50% lower than current price in high 9's. Company has almost no any money, to file NDA at or before end of the year will take another 2mm plus as that is a bottom starting fee with FDA and there is no any guarantee to get approved. No buyer will be interested unless there would be approval with no strings attached. Long and unstable way for Celator.
The company will have hard time to defend this low rate survival with such high price of the treatment. It just doesn't add up and their Vixeos is nothing but only wish to get NDA approved . They didn't meet FDA earlier guidance but they met their own only. people do not see bigger picture , least not yet.